Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

Not all children grow the same way. A new study from the Environmental influences on Child Health Outcomes (ECHO) Program suggests that body weight changes in early childhood may be associated with ...

A hidden link between impulsivity and obesity may not be fixed in human biology but shaped by the cities we live in. Using a novel engineering-based approach, researchers found that ...

Risk of heart failure (HF) has been shown to increase as body mass index (BMI) increases; however, BMI has limitations as an obesity measure. Over median follow-up of 13 years, waist-to-height ratio ...

Obesity causes temporary disruptions, but not permanent structural changes, in the liver’s molecular network that regulates ...

Researchers analyzing data from 915 U.S. cities found that both obesity and impulsivity (measured by ADHD rates) are less ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Researchers used data-driven clustering to define 6 distinct obesity subtypes, offering a potential paradigm shift in how ...

The report provides biotech and pharmaceutical companies that engage in obesity-related therapies a comprehensive analysis of emerging therapeutic strategies, biomarker research developments ...

Wegovy ® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1 ...

New research shows that a vast majority of people with a BMI signifying obesity have substantial excess body fat. Scientists at Johns Hopkins University conducted the study, published this month ...